CIK 0001645460 · Non-accelerated filer<br>Smaller reporting company
Cue Biopharma, Inc.
Sign in to watch- Ticker
- CUE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473324577
- Phone
- 617-949-2680
- Business address
- 100 CHESTNUT STREET, SUITE 300, SOMERVILLE, MA, 02143
- Former names
- Imagen Biopharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $389,304
- in 3 filings
Net −$389,304. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 20 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-05 | Levisetti Matteo Chief Medical Officer | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2024-06-05 | Suri Anish PRESIDENT AND CSO | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2024-06-05 | Fox Michael J Director | Grant or award · Stock Option (right to buy) | +48,800 | 48,800 | ||
| 2024-06-05 | Sandercock Colin SVP, GENERAL COUNSEL | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-06-05 | Millar Kerri-Ann CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-03-06 | Sandercock Colin SVP, GENERAL COUNSEL | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2024-03-06 | Millar Kerri-Ann CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2024-03-06 | Suri Anish PRESIDENT AND CSO | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2024-03-06 | PASSERI DANIEL R CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (right to buy) | +400,000 | 400,000 | ||
| 2024-03-06 | Levisetti Matteo Chief Medical Officer | Grant or award · Stock Option (right to buy) | +260,000 | 260,000 | ||
| 2024-02-20 | Levisetti Matteo Chief Medical Officer | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-01-02 | Garzone Pamela Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2024-01-02 | Kiener Peter A Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2024-01-02 | DRISCOLL FREDERICK W Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2024-01-02 | Verheyen Patrick Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2024-01-02 | Morich Frank Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2023-08-25 | Suri Anish PRESIDENT AND CSO | Purchase | +4,000 | $2.76 | $11K | 135,638 |
| 2023-08-14 | PASSERI DANIEL R CHIEF EXECUTIVE OFFICER | Purchase | +3,000 | $2.86 | $9K | 134,578 |
| 2023-07-21 | Levisetti Matteo Chief Medical Officer | Grant or award · Stock Option (right to buy) | +82,500 | 82,500 | ||
| 2023-07-21 | Millar Kerri-Ann CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +113,000 | 113,000 |
Page 5 of 17 · 323 trades